Joined in 2023 
82 
63 About this deal
Matsuda H, Yuhao, L, Murakami T, and et al. Antiinflammatory effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus Hippocastanum L. Bioorganic Med Chem Lett 1997;7(13):1611-1616. Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection-clinical benefit in patients with chronic deep vein incompetence. Vasa 1992;21:188-92. View abstract. Blanco C, Diaz-Perales A, Collada C, et al. Class I chitinases as potential panallergens involved in the latex-fruit syndrome. J Allergy Clin Immunol 1999;103:507-13. View abstract.
Yoshikawa, M., Murakami, T., Yamahara, J., and Matsuda, H. Bioactive saponins and glycosides. XII. Horse chestnut. (2): Structures of escins IIIb, IV, V, and VI and isoescins Ia, Ib, and V, acylated polyhydroxyoleanene triterpene oligoglycosides, from the seeds of horse chestnut tree (Aesculus hippocastanum L., Hippocastanaceae). Chem Pharm Bull.(Tokyo) 1998;46(11):1764-1769. View abstract. The Scam Detector's algorithm finds neuroflo.com having an authoritative rank of 58.10. It means that the business is Active. Mediocre. Medium-Risk. Unfortunately, it can take many months or even longer to find a treatment that works. Doctors have little guidance to know which ones to start with. That’s why research comparing treatment options is so important — and yet, precious little comparative research on treatments for idiopathic sensory polyneuropathy has been published. Researchers compare four treatments for neuropathy
In-Depth Analysis
Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol 1998;134:1356-60. View abstract.
Kidney disease: There is a concern that horse chestnut might make kidney disease worse. Do not use it if you have kidney problems. The law requires the FDA to have 2 different pathways to approval for medical devices. The PMA pathway is similar to the one for prescription drugs, and requires scientific evidence of safety and efficacy. Only high-risk devices – those that are implantable, life-sustaining or potentially life-saving are reviewed through the PMA process. The 510(k) process is very different: those devices must be substantially equivalent to other medical devices on the market, which are called predicates. As the FDA explained in their memo, medical devices submitted for 510(k) clearance for which no suitable predicate was identified can be reviewed through a 3 rd pathway, called the de novo review, which, to quote the FDA, allows “moderate risk devices without a suitable predicate” to be reviewed with “adequate special controls.”That’s the situation for millions of people who suffer from idiopathic sensory polyneuropathy. The term “idiopathic” means that no cause can be identified; “sensory” refers to the type of nerve, in this case those carrying nerve signals such as pain or temperature; “poly” means “many” and “neuropathy” means nerve disease. So, this is a condition of unknown cause that damages multiple nerves; the most affected nerves tend to be those that provide sensation to the legs and feet. We could go on and on about Shelton’s outright lies, exaggerations of truth, opportunistic marketing tactics, questionable medical diagnosises and rip-off pricing. But, at this point, if you are still considering purchasing anything from Zenith Labs (or any other Shelton-related product), we feel as though we’ve given you the benefit of our investigation. There’s not much more to say other than avoid any product Shelton is trying to sell you. There are most-assuredly, less expensive and more effective treatments available to a consumer who is willing to put just a little more time into researching. Start that research at sandiegocan.org. We’ve done most of the spade-work for you. If You Need to Know More About Shelton’s Scams Overall, nortriptyline and duloxetine appeared to outperform the other drugs in this trial, so they would be good choices to start with rather than pregabalin and mexiletine. But when the best treatments work well for only a quarter or less of patients, and nearly half quit treatment in the first 12 weeks, it’s clear that better, safer, and less expensive treatments are needed.
Great Deal 
New Comment